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is fully funded by National Health System in Portugal since 2001. Since March 2013 
Portuguese electronic prescription system became more generalized, allowing 
central monitoring and validation of medicines prescription and dispensing. This 
database only contains medicines dispensing data in ambulatory setting. TTR-
FAP anonymized patient’s utilization was requested to Administração Central do 
Sistema Saúde(ACSS). International Non-proprietary Names (INN) were extracted 
from INFARMED medicines database. Total and mean annual costs per patient are 
reported in euros. Results: Over the year 2014, a total of 70 286 electronic dispens-
ing activities were imputed to 2013 TTR-FAP anonymized patients in ACSS data-
base. The total cost with TTR-FAP medicines dispensed in ambulatory setting was 
1 612 673 € . The mean annual cost per patient was 801 € (standard deviation 1 233 
€ ). ConClusions: We can conclude that Portuguese ACSS electronic prescription 
database is a useful, relevant and accessible strategy to estimate medicines expendi-
ture trough anonymized individual patient data. Access to additional individual 
patient data such as age/gender would enhance future studies. We can estimate 
that TTR-FAP disease in Portugal accounted for 1 612 673 € total cost in ambulatory 
medicines, with a mean annual cost per patient of 801 € .
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objeCtives: To describe the hospital stays of patients with systemic lupus erythe-
matosus (SLE) in Belgium during one calendar year. Methods: All adult patients 
having ≥ 1 stay with a primary or secondary diagnosis of SLE (ICD-9-CM code 710.0) 
in 2013 were retrieved from the longitudinal IMS Hospital Disease Database (HDD; 
capturing 24% of Belgian hospital beds). All stays generated by these patients 
during the year were retrieved with their characteristics (admission type, associ-
ated diagnoses, in-hospital mortality, length of stay, drugs, procedures, costs) and 
descriptive statistics were derived (mean +/- standard deviation or [interquartile 
range]). Correlation coefficients (Pearson, Spearman) were calculated between 
age, number of stays/patient, total length of stay/patient, annual cost/patient 
and the number of organ systems involved (estimated per patient, based on the 
ICD-9-CM codes of associated diagnoses, further classified into SLE-specific organ 
systems). Results: In 2013, 434 adult SLE patients were identified (82.0% female; 
mean age 54.8 +/- 17.0 years; mean 3.0 [2-4] organ systems involved distributed 
as follows: Musculoskeletal 97.9%, Circulatory/respiratory 54.4%, Mental/Nervous 
system 38.8%, Digestive 31.8%, Renal 29.0%, Haematologic 25.0%, Skin/subcuta-
neous tissue 15.4%, Ophthalmic 6.1%. The mean annual hospitalization cost/
patient was € 8,741 [1,715-9,533]). These patients generated 939 stays (2.2 [1-2] 
stays/patient; 29.7% unplanned admissions; 56.4% full hospitalizations with mean 
length of stay 8.4 days [2-9]). The in-hospital mortality was 2.2% and the mean 
total cost/stay was € 4,069 [366-4,202]). The number of organ systems involved was 
significantly (p< 0.001) correlated to age (Pearson/Spearman: 0.40/0.38), number 
of stays/patient (0.21/0.26), total length of stay (0.57/0.59) and annual cost/patient 
(0.53/0.55). ConClusions: The analysis of real-world hospitalization data showed 
how the burden and complexity of SLE management increases as the organ sys-
tems involvements accrue. Extrapolating the HDD data to the total Belgian popu-
lation, about 1,800 SLE patients might require hospital treatments every year, 
representing a substantial burden for patients and society.
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objeCtives: A myriad of valuation techniques are used by various healthcare 
system stakeholders to appraise drugs. The objective of this evaluation was to 
develop a systematic and evidence-based approach to appraising a drug’s rela-
tive performance. We developed a multi-attribute valuation methodology taking 
into account efficacy, safety and humanistic factors to synthesize relative value 
created by pharmaceutical interventions. We report on our findings for ten onco-
logic therapies. Methods: Health Technology Assessments (HTAs), published trial 
results, and publications archived in PubMed all between 2005 – 2013 were analyzed 
to identify key value attributes. The following five attributes were considered: a) 
Overall Survival (OS), b) Progression Free Survival (PFS), c) Route of Administration, 
d) Trial Comparator, and e) Adverse events. Based on outcomes from clinical tri-
als for each of those attributes for each drug analyzed, the performance of the 10 
oncologic therapies was measured on the selected attributes. We then generated an 
aggregate score for each drug. Drugs were then compared on value score vs. cost of 
treatment to understand the value-cost relationship. Results: The multi-attribute 
analysis and scoring exercise demonstrated that drugs with more than 3 months of 
OS benefit incremental to their clinical trial comparator had higher net value scores, 
whereas PFS without a complementary increment in OS did not significantly impact 
the value score of the drug. Based on a linear model we developed, drug prices 
increased approximately $170/month ($2040/year) for each month of OS improve-
ment. Larger samples will be required to confirm this correlation. ConClusions: 
The framework may be employed to assign a value “score” for cancer drugs that 
may help stakeholders to assess value versus cost of an oncology treatment. Further 
research is needed to compare and contrast this framework with ’other’s such as 
Memorial Sloan Kettering Cancer Center’s “Drug Abacus” framework.
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in 2009: 73% of all costs, cumulatively 300.805,52 EUR (2009-2013). Total average costs 
for period of 5 years (2009-2013) per 1 patient was 48.884,01 EUR. Year-by-year aver-
age costs for 1 patient were as follows: in 2009 24.795 EUR, in 2010 4.682 EUR, in 2011 
3.273 EUR, in 2012 3.630 EUR and in 2013 12.456 EUR. Most influential cost factor was 
average hospitalization/1 patient that dramatically decreased between 2009 and 
2011 (16.651 EUR vs 2.009 EUR) and than increase between 2011 and 2013 (2.009 EUR 
vs 10.531 EUR). We also found negative significant statistical correlation between 
age of patients and costs. ConClusions: We performed first direct costs analysis 
in patients with CF in single center. More data are needed to be able to evaluate 
exact costs associated with CF treatment that should serve as solid background for 
decision making process at national level.
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objeCtives: To analyze the cost of treating invasive fungal infections (IFI) in stem cell 
transplant patients. Methods: Prospective observation cost study from the hospital 
point of view was performed in the major hematology clinic in Sofia for one year 
period. Bottom up cost analysis for the consumed health care resources and their 
cost was performed for all stem cell transplant patients. Medical resources included 
in the analysis was the clinical tests, medical devices, transplantation procedure, 
medicines, blood and blood formulating products, conditioning regime and cost of 
hospital stay. Cost of the resources was taken from the hospital tariff and insurance 
fund charges. Direct medical cost was calculated for the average transplant procedure 
and for the patients when IFI appears. Results: Every patent with hemopoietic stem 
cell transplantation is considered for highly risky for fungal infection appearing due 
to suppressed immune system. Antifungal prophylactic is obligatory for allogenic 
transplantation (n= 27) and for susceptible patients with autologues transplantation 
(n= 64). For allogenic transplantation prophylactic is performed with voriconazole and 
costs 3500 Euro. For the other patients usually fluconazole or itraconazole is used cost-
ing 1600 Euro. The total cost of allogenic transplantation from relative donor is 15000 
Euro, for allogenic transplantation from non-relative is 25000 Euro and for autologues 
transplantation is varying between 10-20 000 Euro. Despite of prophylactics 3 IFIs were 
recorded during one year period and the cost of therapy rise to 50 000 Euro mostly due 
to increase in medicines cost to 66% of total cost. ConClusions: The IFIs are twice 
increasing the average cost of hemopoietic stem cell transplantation mainly due to 
the increase in the cost of medicines to manage the infection.
PSY49
coST AnALYSiS of voriconAzoLe verSuS LiPoSomAL AmPhoTericin B And 
cASPofungin for PrimArY TherAPY of invASive ASPergiLLoSiS Among 
high-riSk hemAToLogic cAncer PATienTS in SAudi ArABiA
Thaqafi AA1, Xue M2, Farahat F1, Gao X2, Wafy MH3, Fahti M3, Ibrahim A3, Charbonneau C4
1NATIONAL GUARD HEALTH AFFAIRS, Riyadh, MD, USA, 2Pharmerit International, Bethesda, 
MD, USA, 3Pfizer, Riyadh, Saudi Arabia, 4Pfizer Inc, Paris, France
objeCtives: Published real-world studies suggest voriconazole may provide reduced 
length-of-stay, intravenous (IV) length-of-therapy (LOT), and costs compared to liposo-
mal amphotericin B (LAMB) and caspofungin in invasive aspergillosis (IA) patients. We 
performed a cost analysis of voriconazole versus LAMB and caspofungin as first-line 
antifungal treatment for IA among patients with prolonged neutropenia or undergo-
ing bone marrow or hematopoietic stem-cell transplantation (BMT/HSCT) from payer 
perspective in Kingdom of Saudi Arabia (KSA). Methods: A decision analytic model 
with a 6-week time horizon was constructed to estimate potential treatment cost of 
alternative interventions voriconazole, LAMB, and caspofungin. Each treatment path-
way was defined by probabilities of an event occurrence and costs (in US$) of clinical 
outcomes derived from published literature, clinical trials, and local expert opinions. 
Patients who failed first-line voriconazole were assumed to have a switch-to or add-on 
of caspofungin; patients who failed LAMB or caspofungin were assumed to have a 
switch-to or add-on of voriconazole. Base-case evaluation included drug management 
costs and additional hospitalization costs due to severe adverse events. Results: 
Based on the clinical trial treatment success rates of 52.8% for voriconazole, 50.0% for 
LAMB, and 33% for caspofungin, as well as assuming first-line 14-day IV treatment 
and 10-day oral treatment for voriconazole, 24-day IV treatment for LAMB, and 24-day 
IV treatment for caspofungin in KSA, voriconazole had a considerable lower total 
treatment cost ($7,654) than LAMB ($16,564) and caspofungin ($17,362). Cost savings 
were primarily due to the lower drug cost, higher treatment efficacy, and shorter IV 
length-of-therapy associated with voriconazole. The cost advantage of voriconazole 
persists through a full-course of the first-line treatment with voriconazole IV (24 
days in KSA), even without oral treatment. ConClusions: This study suggests that 
voriconazole is cost-saving compared to LAMB and caspofungin in the treatment of 
IA from payer perspectives in KSA.
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objeCtives: Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) is a 
rare, progressive, debilitating and life-threatening neurodegenerative disease. 
Treatment for clinical symptoms of the disease is a priority. Although a rare dis-
ease, Portugal has the largest TTR-FAP foci in the world but data on treatment 
costs is lacking. The purpose of this study is to estimate the ambulatory medicines 
costs of TTR-FAP in Portugal. Methods: TTR-FAP patient’s medicines utilization 
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WTPs. For a WTP of $270,000, the P(CE) for the no screen option was .482 with the 
TRI distributions and .535 with our revised distributions. ConClusions: In this 
case, despite the criticism of triangular distributions generally, CEA results were 
not appreciably different qualitatively or quantitatively with the change to more 
accepted distributional assumptions. For an intervention with an ICER closer to 
the CE threshold, the importance may be greater.
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objeCtives: In CP-CML, there are few therapeutic options for highly-resistant 
patients (e.g. third line [3L] or beyond), who have a poor prognosis. Current treat-
ment options are tyrosine kinase inhibitors (TKIs) and allogeneic stem cell trans-
plantation (allo-SCT) for suitable patients. Efficacy of ponatinib, designed to inhibit 
the kinase activity of native BCR-ABL and all mutant variants, including T315I, was 
demonstrated in patients with highly-resistant CML in the pivotal phase II Ponatinib 
Ph+ ALL and CML Evaluation(PACE) trial. In the absence of head-to-head trials, an 
economic model employing a Swedish public healthcare perspective was developed 
to assess the cost-effectiveness of ponatinib for 3L treatment of CP-CML compared 
with current treatment options in Sweden. Methods: The cost-effectiveness 
model compares ponatinib, second-generation TKIs (dasatinib, nilotinib, bosutinib), 
and allo-SCT, with cost per life-years (LY) saved and cost per quality-adjusted life-
years (QALYs) gained as outcome measures, and a lifetime time horizon. Resource 
use includes study drugs, monitoring and follow-up, adverse events and allo-SCT 
procedure. Costs, based on current tariffs in Sweden, and benefits (LY and QALYs) 
projected based on 12-month treatment response, were discounted at 3%/year. 
We performed sensitivity analyses (SA) to identify parameters that most strongly 
influenced results. Clinical validity was evaluated by comparing model-generated 
survival estimates with relevant clinical data. Results: Over the patients’ life-
time, ponatinib provides an increase in LY of almost 7 years and a gain of almost 
4 QALYs compared with the next-best therapy, bosutinib. The incremental cost-
effectiveness ratios range from SEK78,044/QALY gained vs. allo-SCT to SEK351,702/
QALY gained vs. bosutinib. SA showed the model was robust to plausible changes 
in input parameters and had good face validity. ConClusions: This analysis sug-
gests that treating 3L CP-CML with ponatinib provides substantial clinical benefit 
as compared with current alternatives at a reasonable cost, from the perspective 
of the Swedish public healthcare system.
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objeCtives: Biologics are used for the treatment of inflammatory bowel diseases 
(IBDs), Crohn´s disease (CD) and Ulcerative colitis (UC), while their costs are signifi-
cant high. To allocate health spending efficiently, biologics for IBDs are an important 
target for cost-effectiveness analyses. The aim of this study was to systemically 
review the cost-effectiveness of biologics for IBDs and to evaluate the methodo-
logical quality of cost-effectiveness analyses. Methods: The literature search 
was performed to Medline (Ovid), Cochrane Library and SCOPUS in June 2014. The 
cost-utility analyses of biologics for IBDs in adults were included in the review. 
Biologics were compared with conventional medical treatment, another biologic 
treatment, placebo and surgery. Data extraction form was designed beforehand. 
All costs were converted to 2014 euro. The methodological quality of the included 
studies was assessed by Drummond´s checklist, Philips´ checklist and Consolidated 
Health Economic Evaluation Reporting Standards (CHEERS) guideline. Results: 
Of the 1828 references found in the literature search, 25 studies were included in 
the final review. The main causes affected the cost-effectiveness of the biologics 
are the activity of the disease, the duration of the biological treatment and the 
treatment strategy. Among patients refractory to conventional medical treatment 
(CMT) for IBD, incremental cost-effectiveness ratio (ICER) ranged from dominance 
to € 549,335 per Quality-Adjusted Life Year (QALY) compared with CMT. Adalimumab 
produced more frequently lower ICERs than infliximab in comparison with CMT 
for CD. When compared biologics with another biologic treatment for CD, ICER 
ranged from dominance to € 24,012,483/QALY. A study including both direct and 
indirect costs produced more favorable ICERs than studies including only direct 
costs. ConClusions: With a threshold of € 35,000/QALY, current evidence showed 
that biologics are cost-effective for the induction treatment of active and severe 
IBD. Biologics were not cost-effective for moderate IBD. Between biologics the cost-
effectiveness remains unclear.
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objeCtives: A cost-effectiveness analysis (CEA) has been performed, from an 
Italian public payer perspective, to compare the first advanced therapy medici-
nal product (ATMP) containing stem cells for the treatment of Limbal Stem Cell 
Deficiency (LSCD) with conservative treatment, a standard alternative pathway. 
LSCD is a rare condition characterized by the shortage of limbal stem cells in the 
eye resulting in corneal conjunctivalization, corneal opacity, visual impairment and 
even blindness. A medicinal product has been recently approved by EMA as the first 
treatment in moderate-severe LSCD due to chemical or physical burn. Methods: 
Efficacy data derive from a retrospective, case-series, non-randomized, non-con-
1SIHS Health Economics Consulting, Torino, Italy, 2ARIAD Pharmaceuticals Europe Sàrl, 
Epalinges, Switzerland, 3University Hospital of Wales, Cardiff, UK, 4ARIAD Pharmaceuticals, Inc., 
Cambridge, MA, USA, 5Occam Research Ltd, Glasgow, UK
objeCtives: Adults with Philadelphia chromosome-positive (Ph+) acute lympho-
blastic leukaemia (ALL) who develop resistance or intolerance to first- and second-
generation tyrosine-kinase inhibitors (TKIs) may be eligible for potentially curative 
allogeneic hematopoietic stem cell transplantation (alloHSCT) if remission of the 
disease is achieved. The third-generation TKI ponatinib has been shown to be safe 
and efficacious in TKI resistant and intolerant patients, with 47% achieving a major 
cytogenetic response (MCyR). Accordingly, ponatinib followed by alloHSCT in those 
who achieve MCyR represents a potential therapeutic alternative to best supportive 
care (BSC) with standard chemotherapy only. Methods: A Markov cohort model 
was constructed to assess the cost-effectiveness after dasatinib failure of ponatinib 
followed by alloHSCT in patients who achieve MCyR, versus BSC. Direct medical 
costs for ponatinib, BSC, alloHSCT, monitoring and follow-up, and adverse events 
were considered from the perspective of the UK National Health Service. Treatment 
outcomes were estimated from data for the Ph+ ALL patients in a phase 2 ponatinib 
trial (PACE), alloHSCT recipients in the LALA-94 trial, and a historical cohort receiv-
ing BSC. In the absence of valuations for Ph+ ALL health states, utilities for blast-
phase chronic myeloid leukaemia were used. Outcomes were evaluated in terms 
of life-years (LY) and quality-adjusted life-years (QALYs), and cost-effectiveness 
in terms of life-years gained (LYG) and QALYs gained. Results: Patients in the 
ponatinib plus alloHSCT arm had higher overall survival (4.14 versus 0.32 LY) and 
QALYs (2.57 versus 0.09) than BSC, at an increased cost (£88,553 versus £21,208). 
Incremental cost-effectiveness ratios were £17,700/LYG and £27,200/QALY gained 
relative to BSC. ConClusions: Given the assumptions and limitation of this 
analysis, our results suggest ponatinib may offer improved survival and health-
related quality-of-life by enabling patients with Ph+ ALL who have failed dasatinib 
to achieve remission and benefit from alloHSCT, at a moderate increase in cost 
compared with BSC.
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objeCtives: To assess the cost-effectiveness of romiplostim as treatment for 
adult ITP splenectomized patients with refractory disease or non-splenectomized 
patients with surgery contra-indication, in comparison with the use of Intravenous 
Immunoglobulin (IVIg) rescue therapy only, from the Brazilian private health 
care perspective. Methods: A cost per response model was developed. Overall 
response rates were derived from the romiplostim clinical trials (Kuter 2008) and 
were weighted by the proportion of patients splenectomized or not. The use of IVIg 
as rescue therapy in both arms was derived from Pullarkat, 2009. Treatment cost 
was calculated assuming drug wastage for an average patient weight of 72.4Kg and 
height of 170cm. Bleeding rates according to severity and site (gastrointestinal, 
intracranial and other) were estimated for patients without response considering 
data from Weitz, 2012. Resources and procedures used for the treatment of bleed-
ing events were based on a medical specialist group recommendation and costs 
were obtained from official Brazilian databases. Gynecological bleed was used as 
a proxy for costs of other inpatient bleeds. The analysis assumed 50% splenecto-
mized patients and was performed over a time horizon of 24 weeks. Results: The 
average cost per patient over 24 weeks was R$60,509 for romiplostim (including 
rescue therapy and bleeding events costs) and R$173,319 for IVIg. 83.2% and 7.1% 
of patients in the romiplostim and IVIg arm respectively achieved overall response, 
leading to a cost per response equal to R$72,727 for romiplostim compared with 
R$2,424,047 for IVIg as rescue therapy. ConClusions: The use of romiplostim in 
the treatment of ITP increases and maintains the platelet level of splenectomized 
and non-splenectomized patients and, at the same time, reduces the need of 
rescue therapy as IVIg. That generates cost savings and positions romiplostim as 
a dominant (less costly and more effective) strategy when compared with IVIg 
rescue therapy only.
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Alzarea A, Alolayan S, Almutairi H, Alqahtani SS, Rittenhouse B
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objeCtives: In 2009 Yoo and Grosse (Y/G) compared screening/no screening for 
CAH in a CEA, including a PSA using triangular distributions with minimum (MIN), 
mode and maximum (MAX) values for parameters. These distributions have been 
criticized for use in PSAs (Briggs et al). This research reproduces the Y/G analysis 
and then conducts a PSA with more appropriate distributional assumptions to 
evaluate potential bias from triangular distributions. Methods: We limited our 
reanalysis to a change in distributions to focus on the question of distributional 
sensitivity. For parameters in Y/G with symmetric triangular distributions (MIN 
and MAX values equidistant from their mean/mode), we used a normal distribu-
tion with the same mean and chose a Standard Error based on a 95% confidence 
interval defined by the MIN and MAX values of the triangular. For non-symmetric 
distributions, we fit a beta distribution to the triangular, keeping the means equal 
and ensuring that the tails of the distributions extended slightly beyond the MIN 
and MAX of the triangular. Results: We reproduced the Y/G deterministic ICER 
($292,841 vs. Y/G reported $292,000). We also reproduced the triangular distribu-
tion-based PSA ICER from Y/G (256,947 vs Y/G $255,700). In our revised PSA, our 
mean ICER was higher ($273,187), but the CEACs were nearly superimposable. For 
low Willingness to Pay (WTP) values, the probability of being cost-effective - P(CE) 
- was very similar between the two analyses. There was some divergence at higher 
